Arcutis Biotherapeutics, Inc.
ARQT
$26.23
$0.311.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 23.21% | -17.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 23.21% | -18.61% | |||
| Cost of Revenue | 11.80% | -16.29% | |||
| Gross Profit | 24.38% | -18.84% | |||
| SG&A Expenses | 10.88% | -6.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.92% | 3.03% | |||
| Operating Income | 280.76% | -149.43% | |||
| Income Before Tax | 235.20% | -162.70% | |||
| Income Tax Expenses | 46.24% | -80.21% | |||
| Earnings from Continuing Operations | 232.88% | -164.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 232.88% | -164.93% | |||
| EBIT | 280.76% | -149.43% | |||
| EBITDA | 299.27% | -145.00% | |||
| EPS Basic | 231.73% | -164.38% | |||
| Normalized Basic EPS | 234.01% | -162.11% | |||
| EPS Diluted | 226.00% | -170.29% | |||
| Normalized Diluted EPS | 228.84% | -165.74% | |||
| Average Basic Shares Outstanding | 0.89% | 0.87% | |||
| Average Diluted Shares Outstanding | 5.05% | -4.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||